Greenleaf Trust Has $1.86 Million Position in Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Greenleaf Trust raised its holdings in Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 400.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 117,611 shares of the company’s stock after buying an additional 94,113 shares during the period. Greenleaf Trust’s holdings in Dr. Reddy’s Laboratories were worth $1,857,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in RDY. Robeco Institutional Asset Management B.V. increased its stake in Dr. Reddy’s Laboratories by 453.8% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company’s stock valued at $180,620,000 after buying an additional 9,373,412 shares during the last quarter. Artemis Investment Management LLP increased its stake in Dr. Reddy’s Laboratories by 398.3% in the 4th quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock valued at $4,666,000 after buying an additional 236,224 shares during the last quarter. Fisher Asset Management LLC increased its stake in Dr. Reddy’s Laboratories by 59.4% in the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock valued at $39,034,000 after buying an additional 183,146 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Dr. Reddy’s Laboratories by 219.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 155,481 shares of the company’s stock worth $12,353,000 after purchasing an additional 106,796 shares during the last quarter. Finally, Nordea Investment Management AB increased its stake in shares of Dr. Reddy’s Laboratories by 441.8% during the 4th quarter. Nordea Investment Management AB now owns 125,363 shares of the company’s stock worth $1,992,000 after purchasing an additional 102,226 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

Dr. Reddy’s Laboratories Stock Up 0.2 %

Shares of RDY opened at $13.84 on Monday. Dr. Reddy’s Laboratories Limited has a 52 week low of $13.36 and a 52 week high of $16.89. The firm has a market cap of $11.55 billion, a P/E ratio of 22.03 and a beta of 0.51. The firm’s 50-day simple moving average is $14.81 and its 200 day simple moving average is $15.44. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92.

Dr. Reddy’s Laboratories (NYSE:RDY) last announced its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.25% and a return on equity of 17.87%. On average, analysts forecast that Dr. Reddy’s Laboratories Limited will post 0.8 earnings per share for the current year.

Wall Street Analysts Forecast Growth

RDY has been the topic of several recent analyst reports. Nomura lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. StockNews.com lowered shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th. Finally, Barclays lowered their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.